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Hemophagocytic lymphohistiocytosis (HLH) is characterized by uncontrolled 
activation of T cells and macrophages with overproduction of cytokines. Familial HLH 
type2 (FHL2) is the most common form of primary HLH and is caused by mutations in 
PRF1. We have recently described a significant increase in the subpopulation of CD8+ T 
cells with clonal expansion and CD5 down-regulation in Epstein-Barr virus associated-
HLH, which represented a valuable tool for its diagnosis. However, this unusual 
phenotype of CD8+ T cells has not been investigated fully in patients with FHL2. We 
performed immunophenotypic analysis of peripheral blood and measured serum pro-
inflammatory cytokines in 5 patients with FHL2. All patients showed significantly 
increased subpopulations of activated CD8+ T cells with down-regulation of CD5, which 
were negligible among normal controls. Analysis of T-cell receptor Vβ repertoire 
suggested the reactive and oligoclonal expansion of these cells. The proportion of the 
subset declined after successful treatment concomitant with reduction in the serum levels 
of cytokines in all patients except one who continued to have a high proportion of the 
subset and died. These findings suggest that down-regulation of CD5 on activated CD8+ 












EBV, Epstein-Barr virus; FHL, familial hemophagocytic lymphohistiocytosis; HLA, 
human leukocyte antigen; HLH, hemophagocytic lymphohistiocytosis; IM, infectious 
mononucleosis; mAb, monoclonal antibody; NK, natural killer; PE, phycoerythrin; 





Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disease that is 
characterized by marked systemic inflammation and unregulated activation of 
macrophages and T cells [1, 2]. Patients with HLH may present with fever, cytopenia, 
hepatosplenomegaly, liver dysfunction, coagulation abnormalities, and hemophagocytosis 
[1, 2]. HLH is comprised of primary and secondary forms. Primary HLH includes 
familial HLH (FHL), which is caused by genetic defects related to granule-dependent 
cytotoxicity, and immunodeficiencies, such as X-linked lymphoproliferative syndrome. 
Mutations in the PRF1, UNC13D, STX11, and STXBP2 genes cause FHL type 2 (FHL2), 
FHL3, FHL4, and FHL5, respectively. Perforin is a crucial effector molecule for 
cytotoxicity that is present in the granules of cytotoxic T lymphocytes and natural killer 
(NK) cells. FHL2 (perforin deficiency) accounts for more than half of the FHL cases in 
Japan [3]. Secondary HLH is associated with a variety of infections, autoimmune 
diseases and malignancies. Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) is the 
most frequent subtype of HLH in Japan [4]. Establishing a diagnosis of HLH may be 
difficult when based solely on clinical and laboratory findings, because those findings are 
often present in severely ill patients. It is also difficult to differentiate between primary 
and secondary HLH and diagnose a specific subtype of HLH during the acute phase of 
HLH. 
 We have recently reported the clonal proliferation of activated CD8+ T cells with 
down-regulation of CD5 in patients with EBV-HLH [5]. This unique immunophenotype 
of CD8+ T cells could be a valuable tool for the diagnosis of EBV-HLH [5]. However, the 
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immunophenotypic features of T cells in other subtypes of HLH have not been fully 
characterized. Human CD5 is a membrane glycoprotein that belongs to the scavenger 
receptor cysteine-rich family of receptors [6-9]. It is expressed on thymocytes, mature 
peripheral T cells and a small population of B cells, and is involved in the modulation of 
antigen-specific receptor-mediated activation and differentiation signals [6-9]. It has 
recently been reported that CD5 is recruited and colocalized with CD3 at the 
immunological synapse and inhibits T-cell receptor (TCR) signaling in T cells without 
interfering with immunological synapse formation [10]. Although an expanded 
subpopulation of CD8+ T cells lacking expression of CD5 has been reported in a single 
case of FHL2 [11], the nature of CD8+ T cells with down-regulation of CD5 in FLH 
remains to be elucidated. In this report, we describe the down-regulation of CD5 on 
activated CD8+ T cells in patients with FHL2 and discuss the relationship between down-
regulation of CD5 and systemic inflammation. 
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2. Materials and Methods 
 
2.1. Patients 
We studied 5 patients with FHL2 from 5 families, all of whom were born to non-
consanguineous Japanese parents. Table 1 presents the clinical and laboratory data of the 
patients. All patients showed typical features of HLH, such as persistent fever, 
hepatosplenomegaly, cytopenia, liver dysfunction, and hypercytokinemia, i.e., neopterin, 
interferon-γ, and interleukin-6 at the onset of FHL2. Defective NK cell activity was a 
universal feature. In patient P3, HLH was triggered by a primary EBV infection, in which 
the major cellular target of EBV infection, as assessed by in situ hybridization for EBV-
encoded small RNA1was B cells (data not shown) but not CD8+ T cells, resulting in 
marked lymphocytosis with atypical lymphocytes. The disease onset was during early 
infancy in all patients except for patient P4. Patient P2 did not respond to the HLH-2004 
treatment protocol [12], and died at 12 days of age. Patients P1, P3, P4 and P5 underwent 
stem cell transplantation at the ages of 5 mo, 2 yr, 5 mo and 5 mo, respectively [13]. 
Patients P1and P3 are alive with no evidence of disease, but patient P4 died of acute 
graft-versus-host disease 5 months later. In patient P5, the transplantation was performed 
recently. We also investigated 10 cases of EBV-HLH and 13 cases of infectious 
mononucleosis (IM) as disease controls [5, 14]. All patients with EBV-HLH showed 
typical clinical features of HLH and exhibited high viral copy numbers. It was noted that 
CD8+ T cells were the major cellular targets of EBV in all EBV-HLH patients by in situ 
hybridization for EBV-encoded small RNA1 in the available samples. No detectable 
mutations within the SH2D1A or XIAP/BIRC4 genes were observed in the 5 male patients 
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with EBV-HLH [5]. The diagnosis of IM was clinically determined. All patients with IM 
exhibited self-limited disease. Primary EBV infection was serologically confirmed for all 
cases of EBV-HLH and IM. Approval for the study was obtained from the Human 
Research Committee of Kanazawa University Graduate School of Medical Science, and 
informed consent was provided according to the Declaration of Helsinki. 
 
2.2. Flow cytometry 
For the analysis of perforin expression, peripheral blood mononuclear cells 
(PBMCs) were isolated from patients and controls by Ficoll-Hypaque gradient 
centrifugation. PBMCs were stained with fluorescein isothiocyanate-conjugated anti-
CD56 and peridinin chlorophyll protein-conjugated anti-CD3 monoclonal antibodies 
(mAbs). After washing, cells were fixed and permeabilized with Cytofix/Cytoperm Plus 
kit and incubated with phycoerythrin (PE)-conjugated anti-perforin mAb or control Ab 
(BD, San Diego, CA). Perforin expression was evaluated in CD3- CD56+ NK cells with a 
FACSCalibur flow cytometer using CellQuest software (BD Bioscience, Tokyo, Japan). 
For the analysis of CD5 expression, whole blood was stained with fluorescein 
isothiocyanate-conjugated anti-CD5, PE-conjugated anti-human leukocyte antigen 
(HLA)-DR (both from BD), and R-PE-Cy5-conjugated anti-CD4 or anti-CD8 (Dako, 
Glostrup, Denmark) mAbs. CD5 expression on CD8+ T cells was considered negative if it 
was similar to levels of the NK cells and most of the B cells that do not express CD5 [5]. 
Analysis of differences among the data groups was performed using Student’s unpaired t-
test. P-values less than 0.05 were considered significant. Flow cytometric analysis of the 
TCR Vβ repertoire was performed as previously described [15]. 
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2.3. Cytokine determination 
Serum or plasma concentrations of cytokines were determined using the following 
enzyme-linked immunosorbent assay kits: interferon-γ and interleukin-6 (R&D systems, 
Minneapolis, MN); and neopterin (IBL, Hamburg, Germany) [14]. 
 
2.4. Mutation analysis 
DNA was extracted from blood samples using standard methods. The PRF1 gene 
was amplified from genomic DNA using specific primers [16]. Sequencing was 
performed on purified polymerase chain reaction products using the ABI Prism BigDye 
Terminator Cycle sequencing kit on an ABI 3130 automated sequencer (Applied 
Biosystems, Foster, CA). 
 
2.5. Cell cultures 
To stimulate T cells, PBMCs were incubated for 72 h with 5 µg/mL 
phytohemagglutinin, with 1 µg/mL anti-CD3 (OKT3) plus 5 µg/mL anti-CD28 mAb, or 
with 20 ng/mL phorbol myristate acetate plus 250 ng/mL ionomycin in RPMI 1640 





3.1. Perforin expression and PRF1 mutations 
We first analyzed perforin expression by flow cytometry. As shown in Fig. 1, 
perforin was not detectable in NK cells from patients P1, P2, P4 or P5. NK cells from 
patient P3 showed residual expression of the mutated perforin, which might be associated 
with the later age of onset, compared with the other patients. Table 2 presents the 
sequencing data for each patient. Patient P1 was a compound heterozygote bearing 
Leu364fs and Tyr521Cys mutations in PRF1. The effect of the novel missense mutation 
Tyr521Cys was evaluated using a web-based analysis tool, and was found to be 
deleterious on the basis of the SFIT program [18]. Two distinct frameshift mutations, 
Pro333fs and Leu364fs, were demonstrated in patient P2. The former is a novel deletion 
mutation. The 1090_1091delCT (Leu364fs) mutation which was found in patients P1, P2, 
P4 and P5 has been repeatedly reported in Japanese patients with FHL2 [3]. All patients 
had at least one nonsense or frameshift mutation.  
 
3.2. Increased subpopulation of activated CD8+ T cells with down-regulation of CD5 
Immunophenotypic analysis of the lymphocytes demonstrated an increased 
percentage of CD8+ T cells expressing the activation marker HLA-DR in the acute phase 
of the disease (Table1, Fig. 2A). Compared with CD8+ T cells, CD4+ T cells were less 
activated, except for patient P3 who had primary EBV infection. More importantly, the 
activated CD8+ T cells exhibited down-regulation of CD5, which was normally expressed 
on both CD4+ and CD8+ T cells from normal individuals (Fig. 2A, 2B). In contrast to the 
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CD8+ T cells, CD4+ T cells from the patients with FHL2 exhibited normal expression of 
CD5. Although patients with IM have been reported to exhibit marked immune responses 
to regulate EBV-infected B cells and an increased subpopulation of highly activated 
CD8+ T cells, down-regulation of CD5 was not detected in these CD8+ T cells (Fig. 2B) 
[5].  
The percentage of this unique subset (CD5- HLA-DR+ CD8+ T cells) decreased 
after treatment with the HLH-2004 protocol in patient P1 (22.1% to 3.9%), P4 (35.2% to 
0.4%) and P5 (20.3% to 0.8%) concomitant with the relief of clinical symptoms and 
serum levels of neopterin and IFN-γ (Fig. 2C). We did not perform serial analysis in 
patient P3 due to the availability of sample. In contrast, patient P2 did not respond well to 
the treatment and continued to exhibit a high percentage of the subset (58.3% to 63.0%) 
and died at 12 days of age. CD107 cytotoxicity assay was not performed in our patients. 
 
3.3. CD5 expression on normal T cells after in vitro stimulation 
To assess whether down-regulation of CD5 was induced on normal T cells after 
simulation, PBMCs from 3 normal individuals were cultured for 72 hours with 
phytohemagglutinin, anti-CD3 plus anti-CD28 mAbs, or phorbol myristate acetate plus 
ionomycin. Although normal CD8+ T cells expressed activation marker HLA-DR after 
any of the stimulation, CD5 was not down-regulated (Fig. 3). We were not able to 
analyze expression of CD5 after in vitro stimulation using PBMCs from patients with 
FHL2 because no appropriate samples were available, except for from patient P4. No 
down-regulation of CD5 was observed on the stimulated CD8+ T cells from patient P4 
(data not shown). 
 11 
 
3.4. TCR Vβ  repertoire of CD8+ T cells 
We have previously demonstrated that activated and EBV-infected CD8+ T cells 
with down-regulation of CD5 proliferated clonally in patients with EBV-HLH [5]. To 
assess clonality of the CD8+ T cells from patients with FHL2, we investigated the 
diversity of the TCR Vβ repertoire in CD8+ T cells by flow cytometry (Fig. 4A). 
Although a massive expansion of a specific TCR Vβ has often been demonstrated for 
CD8+ T cells from patients with EBV-HLH, CD8+ T cells from patients with FHL2 
exhibited oligoclonal or polyclonal proliferation. Oligoclonal expansion was more 






HLH is a heterogeneous group of diseases that are characterized by uncontrolled 
proliferation of activated macrophages and T cells with overproduction of pro-
inflammatory cytokines [1, 2]. Activated CD8+ T cells are frequently observed during the 
acute phase of HLH. We have recently described the clinical significance of down-
regulation of CD5 on activated and clonally-expanded CD8+ T cells that were 
predominantly infected by EBV in patients with EBV-HLH [5]. However, down-
regulation of CD5 is likely a general consequence of the dysregulated proliferation of 
CD8+ T cells. Increased subpopulations of CD5- CD8+ T cells have been reported in 
patients with allogeneic bone marrow transplantation, human immunodeficiency virus-1 
infection, acute herpes virus infections and peripheral T-cell neoplasma [19-22]. In 
addition, a 17-day-old patient with FHL2 has been reported to exhibit uncontrolled 
proliferation of CD5- CD8+ T cells that showed massive infiltration into the liver [11]. We 
therefore investigated whether this unusual subset of CD5- CD8+ T cells was generally 
present in FHL2, which represents most common form of FHL. 
In the present study, we demonstrated a significant increase in the subpopulation 
of CD5- CD8+ T cells in all patients with FHL2, compared with control participants. These 
cells expressed HLA-DR antigen, indicating an activated phenotype. In contrast to EBV-
HLH in which expanded CD8+ T cells often reacted with a specific TCR Vβ mAb 
reflecting clonal proliferation of EBV-infected cells [5], CD8+ T cells from patients with 
FHL2 exhibited much milder restriction in TCR Vβ repertoire suggesting reactive 
proliferation. This unique subset of CD5- HLA-DR+ CD8+ T cells in FHL2 was detectable 
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only in the acute phase of HLH in which patients exhibited hypercytokinemia, and 
declined progressively after successful treatment concomitant with the levels of serum 
ferritin, soluble IL-2 receptor and pro-inflammatory cytokines. Thus, serial analysis of 
CD5 expression and activation markers on CD8+ T cells may represent an additional 
valuable tool for the follow-up of patients with FHL2. Moreover, this profile might 
provide us with clinical clues to suspect FHL2 during the initial flow cytometric 
assessment of lymphocyte subsets with a small amount of peripheral blood. 
The mechanism underlying down-regulation of CD5 on activated CD8+ T cells 
from patients with FHL2, as well as with EBV-HLH, remains to be elucidated. It is also 
unknown whether CD8+ T cells from other HLH cases exhibit similar profiles during the 
acute phase. Failure of the down-regulation of CD5 on normal CD8+ T cells after in vitro 
stimulation suggests that this profile indicates the highly dysregulated activation and 
proliferation of CD8+ T cells in vivo in the setting of HLH. On the other hand, studies of 
T cells from CD5-deficient mice have reported hyperresponsiveness of CD5- T cells to 
TCR stimulation, suggesting that down-regulation of CD5 might contribute to the 
uncontrolled proliferation of CD8+ T cells in FHL2. Further studies are necessary to 
address these issues. Because a variety of primary and secondary causes of HLH lead to 
similar clinical and biological features, and HLH can range from a self-limited episode to 
a rapidly fatal course [11], it is necessary to identify a parameter that can predict severe 
cases of HLH, for which the timely initiation of life-saving therapy would be required. 
Further investigations are underway to determine whether down-regulation of CD5 on 
activated CD8+ T cells could distinguish severe cases of HLH from other inflammatory 
conditions, including mild cases of HLH. 
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In summary, our studies demonstrate the increased subpopulation of activated 
CD8+ T cells with down-regulation of CD5 in the acute phase of FHL2, and point to an 





We thank Dr. Hirokazu Kanegane for help with sequence analysis, and Ms. 
Harumi Matsukawa and Ms. Shizu Kouraba for their excellent technical assistance. This 
work was supported by a Grant-in-Aid for Scientific Research from the Ministry of 
Education, Culture, Sports, Science and Technology of Japan; and a grant from the 





[1] Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL: How I treat 
hemophagocytic lymphohistiocytosis. Blood 2011;118:4041. 
[2] Usmani GN, Woda BA, Newburger PE: Advances in understanding the 
pathogenesis of HLH. British journal of haematology 2013. 
[3] Nagai K, Yamamoto K, Fujiwara H, An J, Ochi T, Suemori Ket al. : Subtypes of 
familial hemophagocytic lymphohistiocytosis in Japan based on genetic and 
functional analyses of cytotoxic T lymphocytes. PloS one 2010;5:e14173. 
[4] Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura Iet al. : Nationwide 
survey of hemophagocytic lymphohistiocytosis in Japan. International journal of 
hematology 2007;86:58. 
[5] Toga A, Wada T, Sakakibara Y, Mase S, Araki R, Tone Yet al. : Clinical 
significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus 
(EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic 
lymphohistiocytosis. The Journal of infectious diseases 2010;201:1923. 
[6] Bierer BE, Nishimura Y, Burakoff SJ, Smith BR: Phenotypic and functional 
characterization of human cytolytic T cells lacking expression of CD5. The 
Journal of clinical investigation 1988;81:1390. 
[7] Lozano F, Simarro M, Calvo J, Vila JM, Padilla O, Bowen MAet al. : CD5 signal 
transduction: positive or negative modulation of antigen receptor signaling. 
Critical reviews in immunology 2000;20:347. 
 17 
[8] Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lecluse Yet al. : Human 
CD5 protects circulating tumor antigen-specific CTL from tumor-mediated 
activation-induced cell death. Journal of immunology 2007;178:6821. 
[9] Dalloul A: CD5: a safeguard against autoimmunity and a shield for cancer cells. 
Autoimmunity reviews 2009;8:349. 
[10] Brossard C, Semichon M, Trautmann A, Bismuth G: CD5 inhibits signaling at the 
immunological synapse without impairing its formation. Journal of immunology 
2003;170:4623. 
[11] Karandikar NJ, Kroft SH, Yegappan S, Rogers BB, Aquino VM, Lee KMet al. : 
Unusual immunophenotype of CD8+ T cells in familial hemophagocytic 
lymphohistiocytosis. Blood 2004;104:2007. 
[12] Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku Set al. : 
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic 
lymphohistiocytosis. Pediatric blood & cancer 2007;48:124. 
[13] Nishi M, Nishimura R, Suzuki N, Sawada A, Okamura T, Fujita Net al. : 
Reduced-intensity conditioning in unrelated donor cord blood transplantation for 
familial hemophagocytic lymphohistiocytosis. American journal of hematology 
2012;87:637. 
[14] Wada T, Muraoka M, Yokoyama T, Toma T, Kanegane H, Yachie A: Cytokine 
profiles in children with primary Epstein-Barr virus infection. Pediatric blood & 
cancer 2013. 
[15] Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Yet al. : 
Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T 
 18 
lymphocytes in patients with autoimmune thyroid diseases. Clinical and 
experimental immunology 2009;155:166. 
[16] Keerthikumar S, Raju R, Kandasamy K, Hijikata A, Ramabadran S, Balakrishnan 
Let al. : RAPID: Resource of Asian Primary Immunodeficiency Diseases. Nucleic 
acids research 2009;37:D863. 
[17] Wada T, Seki H, Konno A, Ohta K, Nunogami K, Kaneda Het al. : 
Developmental changes and functional properties of human memory T cell 
subpopulations defined by CD60 expression. Cellular immunology 1998;187:117. 
[18] Hijikata A, Raju R, Keerthikumar S, Ramabadran S, Balakrishnan L, Ramadoss 
SKet al. : Mutation@A Glance: an integrative web application for analysing 
mutations from human genetic diseases. DNA research : an international journal 
for rapid publication of reports on genes and genomes 2010;17:197. 
[19] Bierer BE, Burakoff SJ, Smith BR: A large proportion of T lymphocytes lack 
CD5 expression after bone marrow transplantation. Blood 1989;73:1359. 
[20] Indraccolo S, Mion M, Zamarchi R, Coppola V, Calderazzo F, Amadori Aet al. : 
A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in 
peripheral blood of human immunodeficiency virus-infected patients. Clinical 
immunology and immunopathology 1995;77:253. 
[21] Borthwick NJ, Bofill M, Hassan I, Panayiotidis P, Janossy G, Salmon Met al. : 
Factors that influence activated CD8+ T-cell apoptosis in patients with acute 
herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but 
relative maintenance of Bax and Bcl-X expression. Immunology 1996;88:508. 
 19 
[22] Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH: 
Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter 




Table 1. Patient characteristics. 
 P1 P2 P3 P4 P5 Normal range 
 
Onset age 1 month 1 day 2 years 3 months 1 month 
Fever + + + + + 
Hepatosplenomegaly + + + + - 
Hemophagocytosis* + NA + + NA 
Stem cell transplantation + - + + + 
Outcome Alive Deceased Alive Deceased Alive 
Laboratory findings 
     NK cell activity (%) 3.8 2.0 0.0 0.0 0.0 18-40 
     WBC (/µL) 3,100 16,600 51,000 3,330 5,700 5,000-19,500 
     Neutrophils (/µL) 580 13,600  4,290 830 470 3,150-6,200 
     Lymphocytes (/µL) 2,290 1,660 40,800 2,060 4,380 1,500-3,000 
     Hemoglobin (g/dL) 9.2 18.6 8.0 7.8 6.4 9.0-14.0 
 21 
     Platelets (x 103/µL) 86 75 50 18 81 150-350 
     Triglycerides (mg/dL) 356 105 600 129 158 30-149 
     Fibrinogen (mg/dL) 147 117 NA 59 NA 183-381 
     Ferritin (ng/mL) 9,983 532 2,400 1,038 427 4.6-204.0 
     sIL-2R (IU/mL) 3,306 11,209 31,000 18,355 4,180 220-530 
Lymphocyte subsets 
     CD3+ (%) 69.2 87.6 92.6 77.0 66.4 64.4-80.2 
     CD4+ (%) 34.4 40.2 33.5 20.8 29.5 47.3-58.9 
     CD8+ (%) 31.0 42.1 56.8 53.7 25.1 10.3-24.3 
Serum cytokines 
     Neopterin (nmol/L) 60 90 125 120 78 2-8 
     IFN-γ (pg/mL) 37 510 57 1,200 205 < 5 
     IL-6 (pg/mL) 122 18 < 5 52 < 5 < 5 
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NK, natural killer; WBC, white blood cells; sIL-2R, soluble interleukin-2 receptor; IFN-γ, interferon-γ; IL-6, interleukin-6; NA, not 
available. *Hemophagocytosis in bone marrow. 
  
Table 2. PRF1 mutations 
 
 Nucleotide mutation Predicted effect 
 
P1 c.1090_1091delCT p.Leu364fs 
 c.1562A>G p.Tyr521Cys 
P2 c.996_1000delGCCCG p.Pro333fs 
 c.1090_1091delCT p.Leu364fs 
P3 c.1246C>T p.Gly416X 
 c.1349C>T p.Thr450Met 
P4 c.1090_1091delCT* p.Leu364fs 
P5 c.1090_1091delCT* p.Leu364fs 
 





Fig. 1.  Perforin expression. 
Intracellular expression of perforin in CD3- CD56+ NK cells. Thin lines indicate control 
antibody; thick lines represent monoclonal antibody specific for perforin. 
 
 
Fig. 2.  Expression of CD5 by CD8+ T cells.  
 (A) Expression of CD5 and HLA-DR on the CD4+ and CD8+ T cells. The percentage of 
cells gated in each region is shown. (B) The frequency of CD5- HLA-DR+ CD8+ T cells. 
Shown are the percentages of CD5- HLA-DR+ cells among CD8+ T cells in controls (n = 
10), IM (n = 13), EBV-HLH (n = 10), and FHL2 (n = 5). Bars represent the standard 
deviation. *p < 0.01. (C) Correlation between the percentages of CD5- HLA-DR+ CD8+ T 
cells and serum levels of neopterin and IFN-γ. Open symbols indicate data of pre-
treatment (Tx) time points; solid symbols represent those of post-Tx time points. EBV, 
Epstein-Barr virus; FHL2, familial hemophagocytic lymphohistiocytosis type 2; IM, 




Fig. 3.  Expression of CD5 after in vitro stimulation. 
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PBMCs from normal controls were cultured for 72 h with phytohemagglutinin (PHA), 
with anti-CD3 (OKT3) plus anti-CD28 mAb, or with phorbol myristate acetate (PMA) 
plus ionomycin. Expression of CD5 and HLA-DR on CD8+ T cells is shown. 
 
 
Fig. 4.  TCR Vβ  repertoire. 
(A) Peripheral blood samples were stained with monoclonal antibodies (mAbs) for 
individual TCR Vβ together with anti-CD4 and anti-CD8 mAbs. The percentage of TCR 
Vβ expression within the CD8+ T cells was shown. (B) Peripheral blood samples were 
stained with mAbs for individual TCR Vβ subfamilies together with anti-CD8 and anti-
CD5 mAbs. The percentage of TCR Vβ expression within the CD5+ CD8+ and CD5- CD8+ 
T cells from patient P2 at 12 days of age was shown. 
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